Stay updated with breaking news from Iomabb Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Actinium Pharmaceuticals, Inc. (ATNM), Monday announced that its Iomab-B Phase 3 SIERRA trial results demonstrated survival benefit in high-risk relapsed or refractory acute myeloid leukemia patients with TP53 mutations.
Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...